FDA Expert Witness Services

Leverage The Most Trusted FDA Experts in the World

When litigation hinges on FDA compliance and regulatory interpretation, credibility and clarity are everything. ProPharma's expert witness consulting services deliver unparalleled insight, strategic support, and courtroom-ready testimony from the largest team of former FDA and senior industry professionals in the world. Whether you're involved in a business dispute, product liability case, patent issue, or pursuing damages in a regulatory dispute, we provide expert guidance rooted in real-world FDA experience and scientific rigor.

Comprehensive FDA Expertise Across Product Areas

We support legal teams and life sciences clients in a wide range of matters involving FDA-regulated products, including:

  • FDA Enforcement Actions: 483 observations, warning letters, consent decrees, import detentions, and recalls
  • Product Development & Approval Pathways: NDAs, ANDAs, 510(k)s, PMAs, De Novo submissions, and combination product strategies
  • Pharmaceutical, Biotech & Device Litigation: Adulteration, misbranding, product liability, and regulatory negligence claims
  • Advertising & Promotional Compliance: OPDP compliance, off-label promotion, fair balance, and substantiation disputes
  • Clinical Trials & GCP Compliance: Site inspections, data integrity, informed consent violations, protocol deviations
  • Manufacturing & Quality Systems: cGMP/QSR deficiencies, supplier quality, CAPAs, MDRs, and risk management gaps

Our team of FDA Expert Witness Consultants brings an insider’s perspective to every case—identifying gaps, explaining regulatory expectations, and anticipating FDA interpretations that can sway outcomes.

Why Choose ProPharma's Team of FDA Expert Witness Consultants?

Our expert team sets the global standard for FDA-related litigation support. We offer:

Unmatched Regulatory Expertise

Our roster is comprised of more former FDA employees than any other consulting firm—including former reviewers, inspectors, compliance officers, and division directors who understand FDA expectations from the inside out. Our bench also consists of many senior industry executives, with an impressive breadth and depth of scientific and regulatory expertise.

Scientific and Strategic Depth

In addition to regulatory backgrounds, our experts are PhD/MD scientists, clinical trialists, engineers, and manufacturing specialists with deep domain knowledge across the product lifecycle.

Credible, Court Tested Authority

We are the most trusted FDA expert witnesses in the world, with extensive experience supporting clients in federal and state courts, arbitration panels, and regulatory hearings.

Clarity That Persuades

Our consultants translate complex regulatory and scientific concepts into clear, defensible testimony that resonates with judges, juries, and legal counsel alike.

Strategic Support at Every Stage of Litigation

Whether you're building your case or preparing for trial, we serve as a strategic partner throughout the legal process:

  • Early Case Assessment: We help legal teams evaluate regulatory strengths and weaknesses and refine case strategy
  • Expert Reports & Declarations: Our experts craft detailed, objective reports that withstand scrutiny and communicate clearly
  • Deposition & Trial Testimony: Our seasoned experts are skilled at delivering confident, credible testimony that holds up under cross-examination
  • Rebuttal & Opposing Expert Analysis: We review and critique the opinions and assumptions of opposing FDA experts to help you anticipate challenges and build counterpoints

From technical assessments to high-stakes testimony, ProPharma’s expert witness consultants deliver the insight and authority your case needs.

biotech-startup-team-being-shown-a-presentation

Who We Serve

Casually worker business professionals collaborating at a conference table

Our FDA expert witness services are trusted by top-tier clients around the world, including:

  • Law Firms representing pharmaceutical, medical device, biotechnology, and diagnostics companies in civil, criminal, and regulatory matters
  • Life Sciences Companies facing litigation, government investigations, product recalls, or shareholder actions
  • Insurance Providers & Risk Managers seeking defensible analysis of regulatory compliance and product safety claims
  • Litigation Support Firms in need of high-caliber expert evaluation, documentation review, and testimony

When regulatory credibility is on the line, leading firms rely on our unparalleled FDA knowledge and litigation support capabilities.

Partner with the World's Leading FDA Experts

With the largest team of former FDA professionals and globally recognized scientific and regulatory expertise, we are the trusted authority for FDA expert witness support. Our consultants have shaped policy, led inspections, reviewed product submissions, and now help clients succeed in high-stakes litigation.

ProPharma: The World's Leading Regulatory Consultancy

Contact us today to discuss your case and learn how our experts can strengthen your legal strategy with insight that only firsthand FDA experience can provide.

News & Insights

First Joint Clinical Assessments (JCAs): Key Lessons for EU HTA

July 14, 2026

First Joint Clinical Assessments (JCAs): Key Lessons for EU HTA

Learn what the first EU Joint Clinical Assessments reveal about evidence planning, PICO strategy, and HTA readiness for successful market access.

Turning Regulatory Complexity into Predictable Study Start-Up Execution

July 13, 2026

Turning Regulatory Complexity into Predictable Study Start-Up Execution

Explore how organizations can navigate regulatory complexity in clinical trials to achieve predictable study start-up timelines and operational excellence.

Regulatory Readiness as a Strategic Advantage in European Study Start-Up

July 6, 2026

Regulatory Readiness as a Strategic Advantage in European Study Start-Up

Discover how regulatory readiness has evolved into a strategic advantage for clinical study start-ups in Europe, impacting timelines and operational efficiency.

ProPharma Advances Technology Enablement Strategy with AI-Assisted Capability for ANDA Submission Development

July 8, 2026

ProPharma Advances Technology Enablement Strategy with AI-Assisted Capability fo...

ProPharma unveils an AI-assisted capability to enhance ANDA submission development, improving efficiency and maintaining regulatory excellence for clients.

ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and HTA Capabilities

June 18, 2026

ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and H...

ProPharma welcomes Kevin van Dooren as Vice President, HEOR and Market Access, strengthening integrated EU regulatory, HTA, reimbursement, and market access capabilities for life sciences companies.

ProPharma Appoints Adrian Pencak as Chief Commercial Officer

May 27, 2026

ProPharma Appoints Adrian Pencak as Chief Commercial Officer

ProPharma announces Adrian Pencak as Chief Commercial Officer, bringing 25 years of leadership experience to enhance global commercial capabilities and client partnerships.

ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Case Study Ensuring Continuity of Neonatal Vitamin Prophylaxis During a Product Shortage: A Regulatory and Pharmacovigilance-Led Solution - ProPharma

July 15, 2026

Ensuring Continuity of Neonatal Vitamin Prophylaxis During a Product Shortage: A...

Product shortages involving essential medicines can create significant clinical and regulatory challenges, particularly when vulnerable patient populations depend on uninterrupted access to...

Case Study Meeting Patients Where They Are: Delivering Global Clinical Support for Time-Sensitive Research - ProPharma

June 17, 2026

Meeting Patients Where They Are: Delivering Global Clinical Support for Time-Sen...

Conducting clinical research for rare pediatric populations presents unique operational challenges, particularly when eligible patients may be born anywhere in the world and require immediate...

Case Study Accelerating Commercial Readiness for a Novel Cell Therapy Program - ProPharma

June 10, 2026

Accelerating Commercial Readiness for a Novel Cell Therapy Program

As advanced therapy developers move from research-stage operations toward commercialization, they often face significant challenges in scaling quality systems, aligning regulatory strategy, and...

Tech Meets Touch: Evaluating Empathy and AI in Medical Information Delivery

June 4, 2026

Tech Meets Touch: Evaluating Empathy and AI in Medical Information Delivery

Artificial intelligence (AI) is a hot topic in Medical Information (MI), yet real-world evidence of its impact in regulated, human-led MI environments remains limited. Hear practical, evidence-based...

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

June 2, 2026

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

April 23, 2026

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...

News & Insights

First Joint Clinical Assessments (JCAs): Key Lessons for EU HTA

July 14, 2026

First Joint Clinical Assessments (JCAs): Key Lessons for EU HTA

Learn what the first EU Joint Clinical Assessments reveal about evidence planning, PICO strategy, and HTA readiness for successful market access.

Turning Regulatory Complexity into Predictable Study Start-Up Execution

July 13, 2026

Turning Regulatory Complexity into Predictable Study Start-Up Execution

Explore how organizations can navigate regulatory complexity in clinical trials to achieve predictable study start-up timelines and operational excellence.

Regulatory Readiness as a Strategic Advantage in European Study Start-Up

July 6, 2026

Regulatory Readiness as a Strategic Advantage in European Study Start-Up

Discover how regulatory readiness has evolved into a strategic advantage for clinical study start-ups in Europe, impacting timelines and operational efficiency.

Previous Post Arrow Next Post Arrow
ProPharma Advances Technology Enablement Strategy with AI-Assisted Capability for ANDA Submission Development

July 8, 2026

ProPharma Advances Technology Enablement Strategy with AI-Assisted Capability fo...

ProPharma unveils an AI-assisted capability to enhance ANDA submission development, improving efficiency and maintaining regulatory excellence for clients.

ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and HTA Capabilities

June 18, 2026

ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and H...

ProPharma welcomes Kevin van Dooren as Vice President, HEOR and Market Access, strengthening integrated EU regulatory, HTA, reimbursement, and market access capabilities for life sciences companies.

ProPharma Appoints Adrian Pencak as Chief Commercial Officer

May 27, 2026

ProPharma Appoints Adrian Pencak as Chief Commercial Officer

ProPharma announces Adrian Pencak as Chief Commercial Officer, bringing 25 years of leadership experience to enhance global commercial capabilities and client partnerships.

Previous Post Arrow Next Post Arrow
ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Previous Award Arrow Next Award Arrow
Case Study Ensuring Continuity of Neonatal Vitamin Prophylaxis During a Product Shortage: A Regulatory and Pharmacovigilance-Led Solution - ProPharma

July 15, 2026

Ensuring Continuity of Neonatal Vitamin Prophylaxis During a Product Shortage: A...

Product shortages involving essential medicines can create significant clinical and regulatory challenges, particularly when vulnerable patient populations depend on uninterrupted access to...

Case Study Meeting Patients Where They Are: Delivering Global Clinical Support for Time-Sensitive Research - ProPharma

June 17, 2026

Meeting Patients Where They Are: Delivering Global Clinical Support for Time-Sen...

Conducting clinical research for rare pediatric populations presents unique operational challenges, particularly when eligible patients may be born anywhere in the world and require immediate...

Case Study Accelerating Commercial Readiness for a Novel Cell Therapy Program - ProPharma

June 10, 2026

Accelerating Commercial Readiness for a Novel Cell Therapy Program

As advanced therapy developers move from research-stage operations toward commercialization, they often face significant challenges in scaling quality systems, aligning regulatory strategy, and...

Previous Resource Arrow Next Resource Arrow
Tech Meets Touch: Evaluating Empathy and AI in Medical Information Delivery

June 4, 2026

Tech Meets Touch: Evaluating Empathy and AI in Medical Information Delivery

Artificial intelligence (AI) is a hot topic in Medical Information (MI), yet real-world evidence of its impact in regulated, human-led MI environments remains limited. Hear practical, evidence-based...

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

June 2, 2026

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

April 23, 2026

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...

Previous Webinar Arrow Next Webinar Arrow